Utility of ASNS gene methylation evaluated with the HPLC method as a pharmacogenomic biomarker to predict asparaginase sensitivity in BCP-ALL
Open Access
- 15 October 2023
- journal article
- research article
- Published by Taylor & Francis in Epigenetics
- Vol. 18 (1) , 2268814
Abstract
Asparaginase is an important agent for the treatment of acute lymphoblastic leukaemia (ALL), but it is occasionally associated with severe adverse events. Thus, for safer and more efficacious therapy, a clinical biomarker predicting asparaginase sensitivity is highly anticipated. Asparaginase depletes serum asparagine by deaminating asparagine into aspartic acid, and ALL cells are thought to be sensitive to asparaginase due to reduced asparagine synthetase (ASNS) activity. We have recently shown that allele-specific methylation of the ASNS gene is highly involved in asparaginase sensitivity in B-precursor ALL (BCP-ALL) by using next-generation sequence (NGS) analysis of bisulphite PCR products of the genomic DNA. Here, we sought to confirm the utility of methylation status of the ASNS gene evaluated with high-performance liquid chromatography (HPLC) analysis of bisulphite PCR products for future clinical applications. In the global methylation status of 23 CpG sites at the boundary region of promoter and exon 1 of the ASNS gene, a strong positive correlation was confirmed between the mean percent methylation evaluated with the HPLC method and that with the NGS method in 79 BCP-ALL cell lines (R2 = 0.85, p = 1.3 × 10-33) and in 63 BCP-ALL clinical samples (R2 = 0.84, p = 5.0 × 10-26). Moreover, methylation status of the ASNS gene evaluated with the HPLC method was significantly associated with in vitro asparaginase sensitivities as well as gene and protein expression levels of ASNS. These observations indicated that the ASNS gene methylation status evaluated with the HPLC method is a reliable biomarker for predicting the asparaginase sensitivity of BCP-ALL.Keywords
Funding Information
- Japan Society for the Promotion of Science Kakenhi Grant (JP17K17774, JP19H03615)
This publication has 28 references indexed in Scilit:
- Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemiaBlood, 2012
- Genome-wide analysis of DNA methylation patternsDevelopment, 2007
- Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginaseJournal of Clinical Investigation, 2007
- Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemiaBlood, 2006
- Long-Term Results of a Randomized Trial on Extended Use of High Dose l-Asparaginase for Standard Risk Childhood Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2005
- Asparaginase Antibody and Asparaginase Activity in Children With Higher-Risk Acute Lymphoblastic LeukemiaJournal of Pediatric Hematology/Oncology, 2004
- Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer---Children's Leukemia Group phase 3 trialBlood, 2002
- Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01Blood, 2001
- Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemiaThe Lancet, 1991
- Four-Agent Induction and Intensive Asparaginase Therapy for Treatment of Childhood Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 1986